Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-05 pm EDT			5-day change	1st Jan Change
73.44 ^USD	+1.31%		-5.35%	-26.15%

Sep. 05	Such a long wait
Sep. 05	Moderna: CHMP gives green light to new Covid vaccine	CF

Moderna: CHMP gives green light to new Covid vaccine

September 05, 2024 at 10:20 am EDT

Moderna has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for the authorization of its updated COVID-19 mRNA vaccine, Spikevax, targeting the JN.1 variant.

This vaccine is intended for people aged six months and over for the autumn/winter 2024-2025 season. This decision is based on preclinical and clinical data demonstrating the vaccine's efficacy and safety.

Moderna has already obtained similar approvals in Japan, Taiwan and the UK, and continues to submit applications elsewhere. In the EU, the company is participating in a tender for Covid vaccines.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MSCI TAIWAN (STRD)	780.78 USD	+2.10%	-5.19%	-
	MODERNA, INC.	73.44 USD	+1.31%	-5.35%	28.23B

Latest news about Moderna, Inc.

Such a long wait	Sep. 05
Moderna: CHMP gives green light to new Covid vaccine	Sep. 05	CF
Moderna Says Updated COVID-19 Vaccine Receives EMA Backing for EU Approval	Sep. 05	MT
Moderna's JN.1-adapted COVID-19 Shot Backed for EU Approval	Sep. 05	MT
Moderna's JN.1-adapted COVID-19 Shot Backed for EU Approval	Sep. 05	MT
Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1	Sep. 05	CI
Moderna: green light for new Covid vaccine in the UK	Sep. 03	CF
Moderna's Updated Spikevax Receives UK Approval for JN.1 COVID-19 Subvariant	Sep. 03	MT
Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1	Sep. 03	CI
UK Regulator Clears Moderna's Updated COVID-19 Vaccine for JN.1 Variant	Sep. 03	MT
Moderna's Updated COVID-19 Vaccine for JN.1 Variant Wins UK Nod	Sep. 03	MT
Moderna Says Taiwan Approved Updated COVID-19 Vaccine	Sep. 03	MT
Moderna: Taiwan FDA approves new Covid vaccine	Sep. 02	CF
Taiwan FDA Approves Moderna's Updated Spikevax for COVID-19 Variant JN.1	Sep. 02	MT
Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1	Sep. 02	CI
Moderna: Covid awareness campaign in the USA	Aug. 30	CF
Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine	Aug. 29	CI
HSBC Upgrades Moderna to Hold From Reduce, Price Target is $82	Aug. 28	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Aug. 23	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Aug. 23	MT
Sector Update: Health Care	Aug. 23	MT
Moderna: EU green light for RSV mRNA vaccine	Aug. 23	CF
Moderna Wins European Commission Approval for Respiratory Syncytial Virus Vaccine	Aug. 23	MT
Sector Update: Health Care Stocks Rise Premarket Friday	Aug. 23	MT
Market on edge, anticipating Powell's play	Aug. 23

Chart Moderna, Inc.

Duration

Period

More charts

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Employees

5,600

Sector

Biotechnology & Medical Research

Calendar

2024-09-12 - R&D Day

Related indices

S&P 500

More about the company